497 terminated. 497 Phase 1, 175 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 497 | Terminated 497 |
| Phase 2 | 175 | Terminated 175 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study of Inhaled Afatinib Dimaleate PK Profile Afatinib Dimaleat, inhalation of afatinib dimaleate - Lung Cancer, Oral Cancer | Phase 1 | Terminated | Petrov, Andrey | 4 | 2025-11-09 | 2026-06-03 |
| Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin) - Lung Cancer, Non-Small Cell | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 2 | 2025-10-10 | 2026-09-03 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer BG-60366 - Non-Small Cell Lung Cancer, Lung Cancer | Phase 1 | Terminated | BeOne Medicines | 33 | 2024-12-05 | 2026-05-22 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation AZD0022, Cetuximab - Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Terminated | AstraZeneca | 17 | 2024-10-18 | 2026-03-18 |
| A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers [68Ga]Ga-EVS459, [177Lu]Lu-EVS459 - Ovarian Cancer, Lung Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 4 | 2024-09-08 | 2026-07-09 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors PF-08052666 - Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 19 | 2024-08-02 | 2026-07-07 |
| A Study of PHN-010 in Patients With Advanced Solid Tumors PHN-010 - Lung Cancer, Colon Cancer | Phase 1 | Terminated | Pheon Therapeutics | 26 | 2024-07-01 | 2026-01-29 |
| A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients TRX-221 - Carcinoma, Non-Small-Cell Lung, EGFR Mutant Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Therapex Co., Ltd | 19 | 2024-06-14 | 2026-04-02 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors ASP4396 - Solid Tumor | Phase 1 | Terminated | Astellas Pharma Inc | 60 | 2024-04-16 | 2026-10-23 |
Showing 20 of 497. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (388) · Lung Neoplasms (136) · Melanoma (78) · Colorectal Neoplasms (76) · Small Cell Lung Carcinoma (69) · Ovarian Neoplasms (62) · Neoplasms (61) · Neoplasm Metastasis (59) · Breast Neoplasms (55) · Squamous Cell Carcinoma of Head and Neck (53) · Carcinoma, Renal Cell (46) · Triple Negative Breast Neoplasms (44) · Stomach Neoplasms (40) · Pancreatic Neoplasms (38) · Carcinoma, Transitional Cell (27)
Neoplasms by Site (492) · Respiratory Tract Neoplasms (492) · Respiratory Tract Diseases (488) · Lung Diseases (483) · Neoplasms (436) · Bronchial Neoplasms (433) · Carcinoma, Bronchogenic (432) · Lung Neoplasms (357) · Neoplasms by Histologic Type (194) · Neoplasms, Glandular and Epithelial (162) · Skin Diseases (145) · Skin and Connective Tissue Diseases (145) · Digestive System Diseases (138) · Digestive System Neoplasms (136)
pembrolizumab (55) · Carboplatin (53) · Cisplatin (36) · Pemetrexed (35) · Docetaxel (30) · Nivolumab (26) · Paclitaxel (26) · Etoposide (23) · Erlotinib Hydrochloride (20) · Radiotherapy (19) · Gemcitabine (18) · atezolizumab (18) · Cyclophosphamide (17) · Bevacizumab (12) · durvalumab (12)
Pfizer (28) · National Cancer Institute (NCI) (26) · Novartis Pharmaceuticals (14) · Incyte Corporation (9) · AbbVie (8) · M.D. Anderson Cancer Center (8) · Boehringer Ingelheim (7) · Seagen Inc. (7) · Eli Lilly and Company (6) · Mirati Therapeutics Inc. (6) · Bayer (5) · GlaxoSmithKline (5) · Merck Sharp & Dohme LLC (5) · Amgen (4) · AstraZeneca (4)
United States (419) · Spain (65) · France (48) · United Kingdom (48) · Australia (43) · Canada (39) · Italy (33) · South Korea (33) · Japan (32) · Germany (31) · Belgium (28) · Netherlands (21) · China (19) · Taiwan (19) · Singapore (15)
David S Schrump, M.D. (6) · Arun Rajan, M.D. (3)
PMID 31527168, PMID 15246197, PMID 18628474, PMID 20305636, PMID 20930628, PMID 21502553, PMID 22805331, PMID 22878749, PMID 23147218, PMID 23435876, PMID 24013936, PMID 24285980, PMID 24292447, PMID 24456794, PMID 24636848, PMID 25189481, PMID 25288198, PMID 25845992, PMID 25923550, PMID 26003007, PMID 26309191, PMID 26560486, PMID 26825170, PMID 27544054, PMID 28070718, PMID 28468947, PMID 29119276, PMID 29216356, PMID 29322091, PMID 29594044, PMID 29735994, PMID 29808006, PMID 30736848, PMID 30962222, PMID 31367538, PMID 32438272, PMID 32819975, PMID 32897402, PMID 33357452, PMID 33451977, PMID 33677480, PMID 33883177, PMID 33909232, PMID 33982408, PMID 34552864, PMID 34562230, PMID 34568058, PMID 34686340, PMID 34951522, PMID 34965890
2017 (14), 2019 (11), 2023 (10), 2015 (8), 2014 (6), 2016 (6), 2018 (4), P30CA016672 (4), P30CA015704 (3), U01CA062461 (3), U01CA121947 (3), N01CM00039 (2), N01CM62201 (2), P30CA068485 (2), P30CA072720 (2)